Rota Virus Antigen Combo Diagnostic Device

Name: Canine Parvo/Coron/Rota Virus Antigen Combo Diagnostic Device
Brand: HANGZHOU EVEGEN BIOTECH CO., LTD.
SKU: 1931567745

Zhejiang, ChinaHANGZHOU EVEGEN BIOTECH CO., LTD.

US$0.01-20.00

300 Test

Product profile

Customization

Available

Type

Detection Card

Used for

Parvo Coil Rota Combo Test

Model NO.

VD039

Specimen

Feces or Vomit

Assay Time

5-10 Minutes

Sample

Supply

Delivery Time

3~5days After Get Payment

Storage Temperature

2-30 Degree

Shelf Life

18 Months

Payment

T/T, Western Union, Paypal

Customized

Accpet

Box Size

15cm*10cm*8cm

Packing

80 Boxs/Carton

Carton Size

68cm*44cm*44cm

Transport Package

Carton

Specification

10 Tests per box

Trademark

VET Diagnostix

Origin

China

HS Code

3822001010

Production Capacity

1 Million/ Week

Key features

Triple Virus Detection: Simultaneously detects Parvo, Coron, and Rota virus antigens in dog feces or vomit.

Rapid Result Time: Provides clear results within 5 to 10 minutes of testing.

High Sensitivity: Utilizes sandwich lateral flow immunochromatographic assay for accurate diagnosis.

Easy Operation: Simple procedure requiring only 3 drops of treated sample on the test card.

Customization Available: Accepts OEM and ODM services with customizable material, color, and style.

High Production Capacity: Capable of producing up to 1 million test kits per day.

Flexible Payment Options: Accepts T/T, Western Union, and PayPal for secure transactions.

Company profile

HANGZHOU EVEGEN BIOTECH CO., LTD.

Zhejiang, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2019-01-25 CertifiedNearest Port: Shanghai Port, Ningbo PortAverage Response Time: ≤8.31h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHANGZHOU EVEGEN BIOTECH CO., LTD. is identified as a Chinese factory established in 2016, focused on veterinary rapid diagnostic tests. It reports five production lines, six to ten quality-control staff, export sales representing 71%–90% of total sales, and markets in Southeast Asia, the Middle East, and Europe. The supplier states that it invests in R&D and works with professional veterinary diagnostic teams, but the data also reports only one R&D engineer and five total employees, creating an internal staffing inconsistency. Production lead time is stated as within 15 working days in both peak and off-peak seasons. No certification, after-sales service, customization, or detailed customer-case evidence is provided. One recorded buyer and one trade transaction are listed, which provides limited transaction history.

Supplier typeThe supplier is explicitly classified as a factory and a limited company located in Zhejiang, China. Its stated business scope includes health and medicine, chemicals, and industrial equipment and components, with product keywords centered on veterinary rapid diagnostic tests.

R&D capabilityThe supplier explicitly describes continuous innovation and R&D investment, and states that it has a professional R&D team with more than 10 years of business experience and cooperation with international veterinary diagnostic teams. However, the separate data reports only one R&D engineer, so the scale of current in-house R&D capacity is unclear.

Production capacityThe supplier reports five production lines, a 179.0 m² manufacturing plant, six to ten quality-control staff, and order fulfillment within 15 working days in both peak and off-peak seasons. These stated facilities, production-line, quality-control, and lead-time data support production capability, although the reported five total employees conflicts with the quality-control and production information.

Client casesThe supplier states that it cooperated with international animal diagnostic reagent teams, developed markets in the Mediterranean, Southeast Asia, and South America, and became a recognized veterinary rapid-test brand in the Philippines. Separately, only one buyer and one trade transaction are listed, so independently detailed customer-case evidence remains limited.